First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743

A. Scherpereel; S. Antonia; Y. Bautista; F. Grossi; D. Kowalski; G. Zalcman; A. Nowak; N. Fujimoto; S. Peters; A. Tsao; A. Mansfield; S. Popat; X. Sun; B. Padilla; P. Aanur; M. Daumont; B. Bennett; M. McKenna; P. Baas

doi:10.1016/j.annonc.2020.10.603

First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743

A. Scherpereel, S. Antonia, Y. Bautista, F. Grossi, D. Kowalski, G. Zalcman, A. Nowak, N. Fujimoto, S. Peters, A. Tsao, A. Mansfield, S. Popat, X. Sun, B. Padilla, P. Aanur, M. Daumont, B. Bennett, M. McKenna, P. Baas

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

9 Citations (Web of Science)

Original language	English
Pages (from-to)	S1441-S1441
Number of pages	1
Journal	Annals of Oncology
Volume	31
DOIs	https://doi.org/10.1016/j.annonc.2020.10.603
Publication status	Published - Dec 2020
Event	ESMO Immuno-Oncology Virtual Congress - Duration: 9 Dec 2020 → 12 Dec 2020

Access to Document

10.1016/j.annonc.2020.10.603

Cite this

Scherpereel, A., Antonia, S., Bautista, Y., Grossi, F., Kowalski, D., Zalcman, G., Nowak, A., Fujimoto, N., Peters, S., Tsao, A., Mansfield, A., Popat, S., Sun, X., Padilla, B., Aanur, P., Daumont, M., Bennett, B., McKenna, M., & Baas, P. (2020). First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743. Annals of Oncology, 31, S1441-S1441. https://doi.org/10.1016/j.annonc.2020.10.603

@article{d3009f0ca85345f8a1bc7541f7a9185f,

title = "First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743",

author = "A. Scherpereel and S. Antonia and Y. Bautista and F. Grossi and D. Kowalski and G. Zalcman and A. Nowak and N. Fujimoto and S. Peters and A. Tsao and A. Mansfield and S. Popat and X. Sun and B. Padilla and P. Aanur and M. Daumont and B. Bennett and M. McKenna and P. Baas",

year = "2020",

month = dec,

doi = "10.1016/j.annonc.2020.10.603",

language = "English",

volume = "31",

pages = "S1441--S1441",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

note = "ESMO Immuno-Oncology Virtual Congress ; Conference date: 09-12-2020 Through 12-12-2020",

}

Scherpereel, A, Antonia, S, Bautista, Y, Grossi, F, Kowalski, D, Zalcman, G, Nowak, A, Fujimoto, N, Peters, S, Tsao, A, Mansfield, A, Popat, S, Sun, X, Padilla, B, Aanur, P, Daumont, M, Bennett, B, McKenna, M & Baas, P 2020, 'First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743', Annals of Oncology, vol. 31, pp. S1441-S1441. https://doi.org/10.1016/j.annonc.2020.10.603

First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743. / Scherpereel, A.; Antonia, S.; Bautista, Y. et al.
In: Annals of Oncology, Vol. 31, 12.2020, p. S1441-S1441.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM)

T2 - ESMO Immuno-Oncology Virtual Congress

AU - Scherpereel, A.

AU - Antonia, S.

AU - Bautista, Y.

AU - Grossi, F.

AU - Kowalski, D.

AU - Zalcman, G.

AU - Nowak, A.

AU - Fujimoto, N.

AU - Peters, S.

AU - Tsao, A.

AU - Mansfield, A.

AU - Popat, S.

AU - Sun, X.

AU - Padilla, B.

AU - Aanur, P.

AU - Daumont, M.

AU - Bennett, B.

AU - McKenna, M.

AU - Baas, P.

PY - 2020/12

Y1 - 2020/12

U2 - 10.1016/j.annonc.2020.10.603

DO - 10.1016/j.annonc.2020.10.603

M3 - Abstract/Meeting Abstract

SN - 0923-7534

VL - 31

SP - S1441-S1441

JO - Annals of Oncology

JF - Annals of Oncology

Y2 - 9 December 2020 through 12 December 2020

ER -